Overview

• The study, published on April 28, 2025, in *Cancer Research*, details the discovery of highly accurate urinary biomarkers for detecting prostate cancer using AI and spatial transcriptomics.
• Validated in nearly 2,000 patients, the urine test demonstrates greater precision than the PSA blood test, currently the standard diagnostic tool.
• The non-invasive test can potentially be conducted at home, offering a painless alternative to biopsies and improving patient accessibility.
• Large-scale clinical trials are in planning stages, with discussions to enroll 250,000–300,000 men in the UK over the next eight years to assess real-world performance.
• Prostate cancer is the most diagnosed cancer among UK men, with over 52,000 cases annually; the new test could reduce unnecessary biopsies and improve early detection outcomes.